TCOV
MRSN

Trust Company of Vermont’s Mersana Therapeutics MRSN Stock Holding History

Trust Company of Vermont’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2
Closed -$1K – 782
2020
Q4 		$1K Hold
2
– – ﹤0.01% 740
2020
Q3 		$1K Hold
2
– – ﹤0.01% 732
2020
Q2 		$1K Buy
+2
New +$683 ﹤0.01% 751

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Trust Company of Vermont's MRSN Position: Q1 2021 in Review

Trust Company of Vermont sold out of Mersana Therapeutics (MRSN) in Q1 2021, closing a stake of 2 shares — an estimated $1K sold.

Trust Company of Vermont first reported a position in MRSN in Q2 2020 and held it in 3 quarters. The position peaked at $1K in Q4 2020. 132 funds tracked by Wall St. Rank hold MRSN as of Q1 2021.

  • Trust Company of Vermont reported no remaining Mersana Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Trust Company of Vermont sold 2 Mersana Therapeutics shares in Q1 2021, an estimated $1K.
  • Trust Company of Vermont first reported a position in Mersana Therapeutics in Q2 2020 and held it in 3 quarters.
  • Trust Company of Vermont's Mersana Therapeutics position peaked at $1K in Q4 2020.
  • 132 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2021.

Based on Trust Company of Vermont's 13F filing for Q1 2021, filed 16 Apr 2021.